ADP-A2M4CD8 in advanced cancers
This Phase 1 clinical trial is looking at a new type of immunotherapy called ADP-A2M4CD8. It is designed for adults with advanced cancers that have spread or returned, such as lung, bladder, stomach, oesophageal, head and neck, ovarian, womb, or skin cancer. Immunotherapy uses the body's own immune system to fight disease. In this trial, doctors collect your immune cells, modify them in a specialist laboratory to help them recognise tumour cells, and then return them to your bloodstream through a drip. Because this is an early-stage study, the main goal is to find out if the treatment is safe, discover the best dose to give, and monitor any side effects. Doctors will also check whether the therapy helps slow down or shrink the cancer when other standard treatments have stopped working.
At a glance
What is this study about?
When cancer spreads or comes back after standard treatments, doctors look for new ways to target tumour cells. This clinical trial is testing an experimental treatment called ADP-A2M4CD8. It is an advanced cell therapy designed for people with several types of solid tumours, including cancers of the lung, bladder, stomach, gullet (oesophagus), head and neck, ovaries, womb, and skin.
The therapy works by retraining your body's natural defences. White blood cells called T-cells are taken from your blood and genetically adapted in a laboratory. Scientists add special instructions to these cells so they can hunt down a specific protein often found on tumour cells. Once modified and multiplied, these enhanced cells are given back to you through a drip to help attack the cancer.
This is a Phase 1 trial, which means it is one of the first times this treatment is being tested in humans. The primary focus is safety. Doctors need to find out what dose works best without causing unmanageable side effects. They also want to see how long the modified cells survive in the body and whether they are active against tumours.
Research like this is vital because people with advanced cancers often have very limited treatment choices left. If successful, cell therapies like ADP-A2M4CD8 could provide an important new treatment pathway for people whose cancers no longer respond to chemotherapy or standard immunotherapy.
Key takeaways
- Phase 1 trial testing an experimental immune cell therapy called ADP-A2M4CD8.
- Open to adults aged 18 and older with advanced solid cancers who have tried other therapies.
- Uses your own white blood cells, modified in a lab, to target specific cancer proteins.
- Requires a hospital stay for chemotherapy conditioning and the cell infusion.
- Mainly focuses on finding the safest dose and checking how well the treatment is tolerated.
Who may be eligible?
This trial is open to adults aged 18 and over who have been diagnosed with certain types of advanced cancer. These include non-small cell lung cancer, bladder (urothelial) cancer, melanoma, stomach cancer, oesophageal cancer, head and neck cancer, ovarian cancer, or womb (endometrial) cancer. Generally, participants will have already tried standard treatments that have stopped working.
Because of the way this therapy works, your cancer cells must carry a specific marker (protein), and your tissue type must match the treatment's requirements. Your study doctor can check this using a small sample of your tumour and a blood test. You will also need to be reasonably active and well enough in your day-to-day life to undergo the treatment.
You might not be able to take part if you have serious heart, liver, or kidney problems, active infections, or severe autoimmune conditions. Pregnant or breastfeeding women cannot join, and you must be willing to use effective contraception during the study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have an advanced solid cancer (such as lung, bladder, stomach, gullet, head and neck, ovarian, womb, or skin cancer).
- My cancer has continued to grow despite standard treatments, or I have run out of approved options.
- I am well enough to carry out daily tasks and walk around without significant help.
- I am willing to undergo blood tests and tumour testing to check for specific markers.
What does participation involve?
Taking part in this study involves several clear stages. First, you will have screening tests, including blood tests, heart checks, and scans, to confirm you are eligible. Next, you will have a procedure called leukapheresis, where a machine gently separates and collects some of your white blood cells. These cells are sent to a laboratory to be modified, which usually takes several weeks.
Before receiving your modified cells, you will be admitted to hospital for a short course of chemotherapy over a few days. This clears space in your bone marrow so the new cells can settle and grow. You will then receive the ADP-A2M4CD8 cells through a vein drip. You will need to stay in hospital for monitoring for at least one to two weeks so doctors can watch for any immediate reactions.
After leaving hospital, you will have regular outpatient clinic visits for blood tests and health checks. You will also have routine scans every few months to see how your tumour is responding. Long-term follow-up can continue for several years to track your health and safety.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is ADP-A2M4CD8?
It is an experimental 'T-cell receptor' therapy. It uses your own immune cells, modified in a lab, to help them recognise and attack proteins found on certain cancer cells.
Will I have to stay in hospital?
Yes. You will need to spend some time in hospital while receiving preparatory chemotherapy, during the cell infusion, and for observation afterwards to manage any side effects.
Do I have to pay to take part?
No. Clinical trial treatments and required tests are provided free of charge, though you should ask the team if help is available with travel expenses.
Can I leave the trial if I change my mind?
Yes. You can leave the study at any point. Your decision will not affect your relationship with your healthcare team or your normal cancer care.
How do doctors know if my tumour matches this treatment?
The study team will test an existing biopsy sample of your tumour and take a blood sample to confirm if your body has the right genetic markers for the therapy.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.